| Literature DB >> 31030381 |
Baris Afsar1, Alan A Sag2, Cinar Oztosun3, Masanari Kuwabara4, Mario Cozzolino5, Adrian Covic6, Mehmet Kanbay7.
Abstract
Increasing survival in the chronic kidney disease (CKD) population exposes the bone to the cumulative detrimental sequelae of CKD, now defined physiologically and histopathologically as chronic kidney disease mineral bone disorder (CKD-BMD). This disorder is increasingly recognized as a "nontraditional" driver of morbidity and mortality and presents an opportunity to improve CKD outcomes via research. However, recent advances in the literature on this topic have not yet been collected into a single review. Therefore, this report aims to discuss the disordered renal-bone axis in CKD-BMD, molecular and hormonal drivers, novel treatment strategies, and forthcoming research in a clinician-directed format. A key novel topic will be the unique impact of uric acid on CKD-BMD, which is poised to apply extensive existing research in the uric acid domain to benefit the CKD-BMD population.Entities:
Keywords: FGF-23; Mineral bone disorder; Parathyroid hormone; Uric acid; Vitamin D
Year: 2019 PMID： 31030381 DOI： 10.1007/s40620-019-00615-0
Source DB: PubMed Journal: J Nephrol ISSN： 1121-8428 Impact factor: 3.902